Tag - MTVA

Developments

MetaVia doses first patient in study of DA-1726 in obesity

MetaVia (NASDAQ: MTVA) has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and glucagon receptors. According to MetaVia, Part 3...

April 10, 2026

Developments

MetaVia reports positive results from Phase 1b trial of DA-1726 in metabolic disease

MetaVia (NASDAQ: MTVA) has announced positive, statistically significant results from the eight-week, non-titrated, 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel dual...

January 5, 2026

Tag - MTVA

MetaVia doses first patient in study of DA-1726 in obesity

MetaVia reports positive results from Phase 1b trial of DA-1726 in metabolic disease

Subscribe